MDXG (MiMedx Corp) Earnings growth in current year

The reputation recovery of MiMedx Group, Inc. (MDXG) under new leadership is reflected in the price action, where the current metric is -166.40. The annual earnings per share growth metric demonstrates sensitivity to a narrow specialization in placental products. However, uncertainty regarding FDA regulations and dependence on tissue supplies amplify volatility, necessitating caution when analyzing this chart.

MDXG: MiMedx Group, Inc. Earnings per share growth in current year 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for MiMedx Group Inc (MDXG)

- share price and expert price forecast:

Price MiMedx Group|MDXG - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization MiMedx|MDXG - Enterprise Value

- book capitalization data:

Net Assets per Single Share MiMedx|MDXG - Company Book Value|Market-to-Book Ratio mimedx.com|MDXG - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and valuation multiples information:

MDXG - Net Profit|Company Profit Forecast MiMedx Group, Inc.|MDXG - Price to Earnings Ratio|Projected Price to Earnings MiMedx Group, Inc.|MDXG - PEG Multiple|Company Value to EBITDA MiMedx|MDXG - Operating profit EBITDA|Earnings per share for the last 12 months MiMedx|MDXG - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months mimedx.com|MDXG - Net earnings per share growth this year|Expected earnings per share trend next year MiMedx Group, Inc.

- revenue and sales proceeds data:

MDXG - Revenue and Sales Volume|Company Sales Forecast MiMedx Corp|MDXG - Price-to-Revenue Ratio|Forward Price to Sales MiMedx Group, Inc.

Basic company analysis:MDXG - MiMedx Corp

Analyzing net income per share dynamics is critical for constructing a defensive portfolio, as it measures the annual growth rate of real shareholder returns. For MiMedx Group, Inc. (MDXG), which holds unique patents and FDA protection, the year-over-year percentage change in EPS serves as an indicator of how effectively the company monetizes its technological advantage amid stringent US medical regulations.

Main competitors